|

Letrozole Clinical Trials

48 actively recruiting trials across 23 locations

Also known as: Aromatase Inhibitor Therapy., C17H11N5, CDK4/6 Inhibitor, CGS 20267, Femara +1 more

Pipeline

Early 1: 1Phase 1: 3Phase 2: 19Phase 3: 14Phase 4: 2Phase 1/2: 7

Top Sponsors

  • Novartis Pharmaceuticals4
  • Hoffmann-La Roche3
  • AstraZeneca3
  • University of Washington2
  • Pfizer2

Indications

  • Cancer48
  • Breast Cancer39
  • Metastatic Breast Cancer4
  • HER2-negative Breast Cancer4
  • Endometrial Cancer4

Other15 trials

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Phase 2
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Phase 1/2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Phase 2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Phase 2
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Phase 2
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Phase 2
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Phase 2
Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females
Phase 3
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Phase 2
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy
Phase 4
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Phase 2

Birmingham, Alabama4 trials

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Site

Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Central Alabama Research

Phase 3
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

University of Alabama at Birmingham

Phase 2
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

The Kirklin Clinic of UAB Hospital

Phase 3

Los Angeles, California3 trials

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site

Phase 1/2

Anchorage, Alaska2 trials

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Alaska Womens Cancer Care ( Site 0037)

Phase 2
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Alaska Oncology and Hematology

Phase 3

Duarte, California2 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

Denver, Colorado2 trials

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sarah Cannon Research Institute (Scri) At Health One

Phase 1
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site

Phase 3

Atlanta, Georgia2 trials

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Emory Winship Cancer Institute

Phase 2
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Grady Healthcare System

Early 1

Boston, Massachusetts2 trials

ALPINE: Maintenance Letrozole/Abemaciclib

Beth Israel Deaconess Medical Center

Phase 2
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Massachusetts General Hospital Cancer Center

Phase 2

Daphne, Alabama1 trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Southern Cancer Center, PC

Phase 3

Dothan, Alabama1 trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Research Site

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Phoenix, Arizona1 trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

HonorHealth

Phase 3

Scottsdale, Arizona1 trial

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

HonorHealth

Phase 1

Tucson, Arizona1 trial

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site

Phase 3

Berkeley, California1 trial

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Berkeley Outpatient Center

Phase 2

Burbank, California1 trial

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Disney Family Cancer Center

Phase 3

San Francisco, California1 trial

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

University of California at San Francisco

Phase 3

New Haven, Connecticut1 trial

Study of AVZO-021 in Patients With Advanced Solid Tumors

Yale Cancer Center

Phase 1/2

St Louis, Missouri1 trial

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Siteman Cancer Center at Washington University

Phase 2

Belleville, New Jersey1 trial

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

RWJBarnabas Health Clara Maas Medical Center

Phase 1

Nashville, Tennessee1 trial

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Tennessee Oncology PLLC

Phase 1/2

Dallas, Texas1 trial

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Parkland Hospital

Phase 2

Houston, Texas1 trial

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

M D Anderson Cancer Center

Phase 2

Seattle, Washington1 trial

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.